Leverkusen, 3 November, 2014– Bayer has finished the acquisition of completely of the shares of Dihon Pharmaceutical Group Co certain lifestyle change ., Ltd., Kunming, Yunnan, China, a privately kept pharmaceutical company specializing mainly in over-the-counter dermatology products and organic traditional Chinese medication products for several women’s wellness indications. Bayer paid a price of CNY 3.6 billion . This acquisition is certainly further proof our try to strengthen our Existence Sciences portfolio with strategic bolt-on acquisitions, stated Dr. Marijn Dekkers, CEO of Bayer AG. With the recently finished acquisition of Merck Customer Care, this acquisition techniques us in to the leading placement in the OTC market in China.
Bayer, Regeneron initiate two VEGF Trap-Eye Phase 3 trials in Diabetic Macular Edema Regeneron Pharmaceuticals, Inc. and Bayer Health care announced they have initiated the to begin two Phase 3 medical trials analyzing the efficacy and security of VEGF Trap-Eyes , an investigational brand-new agent for the treating certain eye illnesses, in the treating Diabetic Macular Edema . Kemal Malik, Mind of Global member and Advancement of the Bayer Health care Executive Committee.’ The Phase 3 system in DME expands the businesses' global advancement collaboration for VEGF Trap-Eye.